Davide Massa, Medical Oncologist at The Veneto Institute of Oncology (IOV), shared on LinkedIn:
“Our systematic review and meta-analysis on endocrine therapy in ER-low (ER 1-9%) early Breast Cancer is now published in JNCI.
Current guidelines define breast cancers with ≥1% estrogen receptor (ER) expression as hormone receptor-positive. However, this definition remains debated, as ER-low tumors share several features with triple-negative breast cancer, while the magnitude of benefit from endocrine therapy in this subgroup remains uncertain.
Across 17 studies and >10,000 patients with ER low disease, endocrine therapy was associated with a 33% reduction in the risk of relapse or death and a 22% reduction in the risk of death. In parallel, ER-low tumors showed a >2-fold higher risk of recurrence or death compared with ER-rich (ER ≥10%) disease.
These findings support the consideration of endocrine therapy in ER-low breast cancer, while also highlighting the need for more biology-informed trial designs, allowing these patients to access both endocrine-based treatments and strategies tailored to their higher-risk profile, including immune-active approaches.
Thanks to all co-authors and collaborators!”
Title: Endocrine therapy in early-stage estrogen Receptor-Low breast cancer: a systematic review and Meta-Analysis
Authors: Davide Massa, Edoardo Chiappe, Virginia Delucchi, Fabio Girardi, Eva Blondeaux, Marina La Commare, Valentina Guarneri, Matteo Lambertini, Maria Vittoria Dieci
You can also read:
